AlkermesALKS
Recorded

Alkermes Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration26 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Paul MatteisManaging Director and Head of Therapeutics Research

All right. Thanks, everybody. Happy to be moderating this fireside chat with Blair Jackson, CEO of Alkermes. I'm sure folks know the story decently well, but maybe we can start by just having Blair recap some of the key updates last week from the quarter, and then also looking ahead, what are the next events we should be expecting from this orexin program you have that people seem to be interested in?

Blair JacksonCEO

Yeah. All right. Well, thank you so much. Look, I think it has been a really interesting year for the company. We have had a lot of things happen over the course of the year. We acquired Avadel. We had some positive phase III data on LUMRYZ in IH. We have moved our orexin programs into phase III. And then, just a few weeks ago, we announced some really interesting data in ADHD with ALKS 7290. It has just been a whirlwind of a year, and we are expecting that moving forward. As we move into the next part of the cycle, I think we have something like six programs that are either medium or late stage reporting out over the next 12 months. It is in narcolepsy, it is in ADHD, it is in fatigue. We are looking to file our LUMRYZ application for IH. So there is just so much going on at the company.

Blair JacksonCEO

It is just a really exciting time overall. And it is supported by a commercial business that is going so very well. We have generated over $1.8 billion of revenue this year. We are highly profitable. So, I think for us, as you think of the next little while, it is about execution. It is about pulling all these things over the line, making sure we have high-quality data, high performance from our teams, and so we are able to execute on the story that we have put in front of us.

Paul MatteisManaging Director and Head of Therapeutics Research

Great. The next big readout here is coming in idiopathic hypersomnia. In other conversations we have had, you have talked about how you feel like in NT2, the data you generated might be like sort of a reasonable benchmark for what to expect. Maybe just sort of expound upon your thinking there and your expectations for this mechanism.

Blair JacksonCEO

Yeah. I think it's interesting. Obviously, there hasn't been a lot of studies with orexin agonists in the NT2 or the IH populations. We're sort of leading the way in that category. I think with the NT2 study, we saw a really strong response, both on ESS, on MWT, multiple doses, and we see the IH population being very, very similar. One of the things that drives that is there really is a little bit of a gray line in diagnosis between NT2 and IH. Patients oftentimes will get an IH designation because of a sleep test. If they go test again later, they find they have an NT2 designation. I think there's a lot of overlap between these populations, with the exception of one group. One group that's a little different in IH is the long sleepers.

Blair JacksonCEO

About 25% of the IH population are long sleepers. So they have a lot of naps, but they're not very refreshing, so they suffer from excessive daytime sleepiness. Our expectation, though, is that this mechanism of orexin agonism can still drive wakefulness in those patients, because we see that across all the populations we've studied in. Normal healthy volunteers in the SAD/MAD study, whether it's NT2 population, people who have intact orexin, if you give them super therapeutic levels of orexin agonism, you're able to drive that wakefulness. So, expectation-wise, the way we designed the study is similar power-wise, et cetera, to what we saw with NT2.

Paul MatteisManaging Director and Head of Therapeutics Research

Yeah. Okay. Makes sense. I guess in this population, ESS is the more important endpoint, right? What do we know about that scale and sort of what the benchmark is for something that is clinically significant there on the benefit side?

Blair JacksonCEO

Yeah. It's a good question. None of these scales are perfect, and ESS is one of those subjective scales used by patients. It's a look back of a week, and you have a number of different questions that they look at, which is sort of questions like, "Do you feel like you're going to fall asleep while you're sitting at a traffic light? Do you feel like you're going to fall asleep in a restful situation or when nothing's going on?" It's really measuring how tired they're feeling and how that's impacting their life. So, for this scale, I think typically a 4-point change is considered to be clinically meaningful. I think 6 points is considered moderate. What's important, though, is that this is the scale that physicians use commercially.

Blair JacksonCEO

When you go and you call on a doctor or the patient sees the doctor, they're assessing their performance on that ESS scale. I think what we feel pretty good about is we've seen an ability to move that scale across a number of different patient types. In our NT2 study, which as I said before, I think is a little like this IH group, we saw at our highest dose that we were able to normalize patients from moderate to severe to normal. About 70% of them normalized on our once-daily dose. It does show that this scale's movable, that the mechanism's working in this type of patient population. We're excited to see what we can do in the IH group.

Paul MatteisManaging Director and Head of Therapeutics Research

How important is it that you see a p-value less than 0.05 in this readout?

Blair JacksonCEO

Well, it's an interesting question. Obviously, we designed the study and expect to hit statistics. I think what people need to recognize, though, is this is a phase II study, and we are going to be doing some learning here. To the extent we see anything unexpected, for example, perhaps the long sleepers perform differently than we had anticipated, if we're able to still design and power around that for phase III, we'll take those learnings and we'll move forward with phase III. I think you don't want to be a slave to the statistics, because it kind of could mislead you. This patient group is a group that really doesn't have a lot of drugs available to them, where there's a huge unmet need there. The only branded drug in the space is, right now, XYWAV.

Blair JacksonCEO

I think being an orexin agonist could add a lot to that treatment population.

Paul MatteisManaging Director and Head of Therapeutics Research

Yep. Okay. You have two phase III reading out next year in NT1 and NT2. Maybe one, do you want to talk about just how those studies are enrolling? Then two, in terms of your internal expectations for what these data may deliver on, are the prior phase II studies the right way for us to think about a benchmark here?

Blair JacksonCEO

Yeah. So we kicked off our phase III program in the middle of the summer last year, and our expectation is it is going to take about a year to enroll these studies. So, thinking about middle of summer next year or so being done with them. Enrollment is going really, really well. I mean, we are through the summer shutdowns in Europe, so the European sites are up and running and enrolling patients. That is a very important group for us because, one, it provides a large number of patients, but also the quality of data you get from these European sites is actually really, really good. They tend to have a better handle on the patient types and some of the testing methodology.

Blair JacksonCEO

For the phase III programs, when you look at the overall size of the program and you look at what we are doing from a site perspective, it is really not that much larger than what we did in the phase II. So, we do not expect to see a lot of erosion of signal or a lot of variability because of those things that you see in some of these broader psychiatric indications. So I think the phase I and the phase II levels that we saw, we would expect that it would be something similar to that.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day